Myrbetriq Alternatives Compared
| Myrbetriq (mirabegron) | Oxybutynin | Solifenacin |
|
|---|
| Myrbetriq (mirabegron) | Oxybutynin | Solifenacin |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Myrbetriq may be used to relieve symptoms of overactive bladder in adults such as urinary incontinence and urinary frequency. It may also be used to treat the symptoms of neurogenic detrusor... View more |
Prescription and OTC
Oxybutynin helps to relieve symptoms of an overactive bladder and urinary incontinence but it may cause side effects such as a dry mouth and constipation. Prescribed for Overactive Bladder... View more |
Prescription only
Prescribed for Overactive Bladder, Urinary Incontinence, Urinary Frequency, Neurogenic Bladder, Neurogenic Detrusor Overactivity. Solifenacin may also be used for purposes not listed in this medication guide. View more |
Related suggestions Urinary Frequency
Urinary Incontinence
Neurogenic Detrusor Overactivity
Popular comparisons
|
|||||||||||||||||||||||
| More about Myrbetriq (mirabegron) | More about Oxybutynin | More about Solifenacin | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Myrbetriq has an average rating of 4.8 out of 10 from a total of 276 ratings on Drugs.com. 34% of reviewers reported a positive effect, while 49% reported a negative effect. |
Oxybutynin has an average rating of 6.7 out of 10 from a total of 459 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 24% reported a negative effect. |
Solifenacin has an average rating of 5.5 out of 10 from a total of 205 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 36% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Myrbetriq side effects |
View all Oxybutynin side effects |
View all Solifenacin side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Myrbetriq prices |
View all Oxybutynin prices |
View all Solifenacin prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Oxytrol, Oxytrol for Women | VESIcare, VESIcare LS | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
50 hours |
2.3 hours |
68 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 249 drugs are known to interact with Myrbetriq:
|
A total of 285 drugs are known to interact with Oxybutynin:
|
A total of 495 drugs are known to interact with Solifenacin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
June 28, 2012 |
N/A |
November 19, 2004 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.